Cyclic Peptides Patents (Class 530/317)
  • Publication number: 20140357562
    Abstract: This application describes a family of compounds acting as ?-arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.
    Type: Application
    Filed: August 15, 2014
    Publication date: December 4, 2014
    Inventors: Dennis Yamashita, Xiao-Tao Chen
  • Publication number: 20140348850
    Abstract: The present invention relates to methods of reducing blood pressure in a subject by administering a plasma kallikrein inhibitor.
    Type: Application
    Filed: August 15, 2014
    Publication date: November 27, 2014
    Inventors: Edward P. Feener, Allen Clermont
  • Patent number: 8895695
    Abstract: Template-fixed ?-hairpin peptidomimetics of the general formula (I) wherein Z is a template-fixed chain of 12, 14 or 18 ?-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid), are Gly, NMeGly, Pro or Pip, or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have CXCR4 antagonizing properties. These ?-hairpin peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: November 25, 2014
    Assignees: Polyphor Ltd., Universität Zürich
    Inventors: Jürg Zumbrunn, Steven J. Demarco, Sergio Lociuro, Jan Wim Vrijbloed, Frank Gombert, Reshmi Mukherjee, Kerstin Moehle, Daniel Obrecht, John Anthony Robinson, Heiko Henze, Barbara Romagnoli, Christian Ludin
  • Patent number: 8889826
    Abstract: Disclosed herein are novel peptides and protected peptides. These compounds can be derived from naturally occurring peptides, such as those selected from colistin, circulin A, polymyxin A, polymyxin B, polymyxin D, octapeptin B, octapeptin C, and [Ile7]polymyxin B1. Also disclosed are pharmaceutical compositions containing the new peptides, as well as methods for preparing the novel peptides and protected peptides.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: November 18, 2014
    Assignee: BioSource Pharm, Inc.
    Inventors: Richard A. Leese, Noreen Francis, William V. Curran, Donald B. Borders, Howard Jarolmen
  • Patent number: 8889632
    Abstract: Cross-linked peptides related to human p53 and bind to HMD2 or a family member of HDM2 useful for promoting apoptosis, e.g., in the treatment of and identifying therapeutic agents that binding to HMD2 or a family member of HDM2.
    Type: Grant
    Filed: January 31, 2008
    Date of Patent: November 18, 2014
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Federico Bernal, Loren D. Walensky, Gregory L. Verdine, Susan Korsmeyer
  • Publication number: 20140336069
    Abstract: Peptides useful in determining the presence of autoantibodies in patients suffering from rheumatoid arthritis are disclosed.
    Type: Application
    Filed: May 23, 2014
    Publication date: November 13, 2014
    Applicant: STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN
    Inventors: Waltherus Jacobus Wilhelmus VAN VENROOIJ, Jan Wouter DRIJFHOUT, Martinus Adrianus Maria VAN BOEKEL, Gerardus Jozef Maria PRUIJN
  • Patent number: 8883174
    Abstract: Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a TLR9 agonist and a TLR 2/6 agonist to the individual.
    Type: Grant
    Filed: March 25, 2010
    Date of Patent: November 11, 2014
    Assignee: The Board of Regents, the University of Texas System
    Inventors: Burton Dickey, Michael Tuvim, Scott Evans
  • Publication number: 20140329989
    Abstract: The present invention relates to the preparation of compounds, in particular to the preparation of compounds of formula (I), which may be used with a compound of formula (VI), or a salt thereof as intermediates for the preparation of antifungal agents, preferably micafungin (MICA) or a salt thereof.
    Type: Application
    Filed: September 7, 2012
    Publication date: November 6, 2014
    Applicant: SANDOZ AG
    Inventors: Roland Barth, Kerstin Knepper, Hubert Sturm
  • Patent number: 8877716
    Abstract: The invention relates to peptide derivatives (peptides and pseudo-peptides) and the use thereof as vectors for molecules of interest. The invention also relates to conjugates containing a peptide derivative of the invention bound to a molecule of interest. The peptides of the invention can be used, in particular, to vectorize, generally in the form of prodrug conjugates, molecules of pharmaceutical or diagnostic interest such as, for example, therapeutic molecules, imaging or diagnostic agents, or molecular probes, across cell membranes of different tissues or organs, healthy or pathologic, and in particular to enable their transport across physiological barriers of the nervous system such as the Blood brain barrier (BBB), Blood-spinal cord barrier (BSCB), or Blood-retinal barrier (BRB).
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: November 4, 2014
    Assignees: Vect-Horus, Centre National de la Recherche Scientifique, Universite D'Aix-Marseille
    Inventors: Patrick Vlieghe, Marion David, Yves Molino, Michel Khrestchatisky
  • Publication number: 20140323407
    Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.
    Type: Application
    Filed: May 11, 2012
    Publication date: October 30, 2014
    Applicant: APELLIS PHARMACEUTICALS, INC.
    Inventors: Cedric Francois, Pascal Deschatelets
  • Publication number: 20140315784
    Abstract: The present invention relates to compounds which bind to Beta Trans-ducin repeat-containing protein (PTrCP), and modulate the activity of 13TrCP. In particular, the invention relates to compounds which demonstrate optimised binding to PTrCP. The invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds as medicaments, specifically for the treatment of disorders associated with aberrant protein degradation, such as cancer. The preferred binding inhibitors are peptides derived from the motive DSGXXS, e.g. DEGFWE, DDGFWD and Succinyl-EGFWE.
    Type: Application
    Filed: June 27, 2012
    Publication date: October 23, 2014
    Inventors: Mark Bradley, Jeffrey George Andrew Walton, Sunay Vijaykumar Chankeshwara, Mazen Sleiman, George S. Baillie, Lucien Gibson
  • Patent number: 8865655
    Abstract: A compound of the general Structure (VII) or (VIII) including isoteres and pharmaceutically acceptable salts thereof, wherein R1, R2 (where X=—CONR6—), R3 and R7 are the same or different and each represents an amino-acid side chain moiety; R2 (where X=—CHZ—), R4 and R6 are the same or different and each represents hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl; K represents a linear or branched chain of carbon atoms and containing 1-10 atoms; L represents a moiety capable of chelating zinc in the active site of a histone deacetylase (HDAC) or of conversion to such a moiety in vivo (by hydrolysis or reduction, for example); M is a linear or branched chain of carbon or other atoms and containing 1-10 atoms, and capable of undergoing in vivo cleavage to give Structure (VII); and Z is a heteroatom bonded to the macrocycle by a single or double bond, and any other group bonded to Z is H or a protecting group.
    Type: Grant
    Filed: November 22, 2007
    Date of Patent: October 21, 2014
    Assignee: Karus Therapeutics Limited
    Inventors: Arasu Ganesan, Graham Keith Packham, Alexander Richard Liam Cecil
  • Patent number: 8865656
    Abstract: ?-Hairpin peptidomimetics of the general formula Cyclo(-Xaa1-Xaa2-Xaa3-Cys4-Xaa5-Xaa6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-), disulfide bond between Cys4 and Cys11, and pharmaceutically acceptable salts thereof, with Xaa1, Xaa2, Xaa3, Xaa5, Xaa6, Xaa7, Xaa8, Xaa12, Xaa13, Xaa14, Xaa15 and Xaa16 being amino acid residues of certain types which are defined in the description and the claims, have CXCR4 antagonizing properties and can be used for preventing HIV infections in healthy individuals or for slowing and halting viral progression in infected patients; or where cancer is mediated or resulting from CXCR4 receptor activity; or where immunological diseases are mediated or resulting from CXCR4 receptor activity; or for treating immunosuppression; or during apheresis collections of peripheral blood stem cells and/or as agents to induce mobilization of stem cells to regulate tissue repair.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: October 21, 2014
    Assignee: Polyphor AG
    Inventors: Daniel Obrecht, Frank Gombert, Alexander Lederer, Barbara Romagnoli, Christian Bisang
  • Publication number: 20140308347
    Abstract: The present invention relates to compounds that are cationic vancomycin analogues and their compositions. Method of making the compounds and their use as medicament for the treatment of bacterial infection are also disclosed.
    Type: Application
    Filed: November 13, 2012
    Publication date: October 16, 2014
    Applicant: JAWAHARLAL NEHRU CENTRE FOR ADVANCED
    Inventors: Jayanta Haldar, Yarlagadda Venkateswarlu, Padma Akkapeddi
  • Patent number: 8859723
    Abstract: The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.
    Type: Grant
    Filed: August 13, 2011
    Date of Patent: October 14, 2014
    Assignee: Aileron Therapeutics, Inc.
    Inventors: Vincent Guerlavais, Noriyuki Kawahata
  • Publication number: 20140303343
    Abstract: Disclosed herein are methods of making cyclosporin A Form 2.
    Type: Application
    Filed: June 19, 2014
    Publication date: October 9, 2014
    Inventors: Ke Wu, Scott W. Smith
  • Patent number: 8853357
    Abstract: The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of Streptomyces roseosporus. The invention also discloses high pressure liquid chromatography methods for analysis of daptomycin purity. The invention also discloses lipopeptide micelles and methods of making the micelles. The invention also discloses methods of using lipopeptide micelles for purifying lipopeptide antibiotics, such as daptomycin. The invention also discloses using lipopeptide micelles therapeutically.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: October 7, 2014
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: Thomas J. Kelleher, Jan-Ji Lai, Joseph P. DeCourcey, Paul D. Lynch, Maurizio Zenoni, Auro R. Tagliani
  • Publication number: 20140294819
    Abstract: The present invention provides acyclic polypeptide fragment of CD20 comprising (i) a contiguous amino acid sequence consisting of amino acid residues SEKNS (SEQ ID NO:67); (ii) a first cysteine residue which is present at a region N-terminal to the contiguous amino acid sequence and (iii) a second cysteine residue which is present at a region C-terminal to the contiguous amino acid sequence, wherein the cyclic polypeptide is oxidised by the presence of a disulphide bond formed between the first and second cysteine residues. Also described is the use of the cyclic peptide fragment to generate antibodies which bind specifically to CD20. Antibodies which bind specifically to the cyclic peptide fragment for use in treatment of B-cell mediated conditions in felines and canines are also described.
    Type: Application
    Filed: October 12, 2012
    Publication date: October 2, 2014
    Inventor: David Gearing
  • Publication number: 20140294901
    Abstract: The invention relates to disulfide-rich dimer molecules which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?1 binding.
    Type: Application
    Filed: March 28, 2014
    Publication date: October 2, 2014
    Applicant: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Larry C. Mattheakis
  • Patent number: 8846601
    Abstract: Melanocortin receptor-specific cyclic peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and z are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: September 30, 2014
    Assignee: Palatin Technologies, Inc.
    Inventors: Yi-qun Shi, Shubh D. Sharma, John H. Dodd, Wei Yang, Xin Chen
  • Patent number: 8846607
    Abstract: Formulations have been developed to treat or reduce the spread of respiratory infections, especially chronic or drug resistant infections, particularly tuberculosis (TB), severe acute respiratory syndrome (SARS), meningococcal meningitis, Respiratory syncytial virus (RSV), influenza, and small pox. Formulations include a drug or vaccine in the form of a microparticle, nanoparticle, or aggregate of nanoparticles, and, optionally, a carrier, which can be delivered by inhalation. Giving the drugs via an inhaler sidesteps the problems associated with oral or injectable drugs by bypassing the stomach and liver, and delivering the medication directly into the lungs. In one embodiment, the particle containing the agent is a large porous aerosol particle (LPPs). In another embodiment, the particles are nanoparticles, which can be administered as porous nanoparticle aggregates with micron diameters that disperse into nanoparticles following administration.
    Type: Grant
    Filed: October 19, 2005
    Date of Patent: September 30, 2014
    Assignee: President and Fellows of Harvard College
    Inventors: David A. Edwards, Jennifer Fiegel, Jean Sung
  • Patent number: 8846610
    Abstract: The present invention relates to crystalline and crystal-like forms of lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention relates to methods of purifying lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention also relates to pharmaceutical compositions comprising the purified form of the lipopeptide and methods of using these compositions.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: September 30, 2014
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: Dennis Keith, Jan-Ji Lai, Chandrika Govardhan, Nazer Khalaf
  • Publication number: 20140288266
    Abstract: The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISATX247, and derivatives thereof. ISATX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. Stereoselective pathways may utilize a Wittig reaction, or an organometallic reagent comprising inorganic elements such as boron, silicon, titanium, and lithium. The ratio of isomers in a mixture may range from about 10 to 90 percent by weight of the (E)-isomer to about 90 to 10 percent by weight of the (Z)-isomer, based on the total weight of the mixture.
    Type: Application
    Filed: March 18, 2014
    Publication date: September 25, 2014
    Applicant: Aurinia Pharmaceuticals, Inc.
    Inventors: Selvaraj A. Naicker, Randall W. Yatscoff, Robert T. Foster, Mark Abel, Seetharaman Jayaraman, Hans-Jürgen Mair, Jean-Michel Adam, Bruno Lohri
  • Patent number: 8835375
    Abstract: The invention relates to analogs of angiotensins, in particular to cyclised analogs having Ang(1-8) agonistic or antagonistic activity and to cyclised Ang(1-7) analogs with agonistic or antagonistic activity and displaying improved proteolytic resistance compared to their linear counterparts. Provided is a cyclic angiotensin peptide analog comprising a thioether-bridge linkage between the amino acids corresponding to positions Tyr4 and Pro7 in naturally occurring Angiotensin. Also provided is the use of analogs in therapy, for example hypertension.
    Type: Grant
    Filed: August 7, 2007
    Date of Patent: September 16, 2014
    Assignee: Applied Nanosystems B.V.
    Inventors: Marijke Haas, Leonardus Dorothea Kluskens, Anneke Kuipers, Rick Rink, Sieger Adriaan Nelemans, Gert Nikolaas Moll
  • Publication number: 20140256614
    Abstract: Compositions and methods for activating MK2, augmenting permeability barriers, such as epithelial and/or endothelial barriers, and treating diseases, conditions, disorders, and/or injuries associated therewith, such as pulmonary edema and other lung diseases and injuries are provided herein.
    Type: Application
    Filed: August 16, 2012
    Publication date: September 11, 2014
    Applicant: TUFTS MEDICAL CENTER
    Inventor: Usamah S. Kayyali
  • Patent number: 8828926
    Abstract: Use of constructs which bind to one or more natriuretic peptide receptors and include a plurality of amino acid residues and at least one amino acid surrogate of formula I: where R, R?, Q, Y, W, Z, J, x and n are as defined in the specification, and optionally at least one prosthetic group, for the prophylaxis or treatment of airway diseases, including but not limited to inflammation-related airway diseases, acute asthma or chronic obstructive pulmonary disease, methods of prophylaxis and treatment of airway diseases and pharmaceutical compositions and formulations for the prophylaxis or treatment of airway diseases.
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: September 9, 2014
    Assignee: Palatin Technologies, Inc.
    Inventors: Margarita Bastos, Jennifer Lata, Jeffrey D. Edelson
  • Patent number: 8828413
    Abstract: Novel peptoid oligomers are disclosed that have a formula represented by the following formula I: The peptoids demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present cyclic and linear peptoids are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: September 9, 2014
    Assignee: New York University
    Inventors: Kent Kirshenbaum, Sung Bin Shin
  • Patent number: 8822637
    Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O-)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: September 2, 2014
    Assignee: Novartis AG
    Inventors: Rainer Albert, Wilfried Bauer, David Bodmer, Christian Bruns, Ivo Felner, Heribert Hellstern, Ian Lewis, Mark Meisenbach, Gisbert Weckbecker, Bernhard Wietfeld
  • Patent number: 8822422
    Abstract: An antitumor agent containing, in combination, at least one kind of antitumor agent selected from the group consisting of an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent, and a histone deacetylase inhibitor. According to the present invention, an antitumor agent causing reduced side effects and having a superior antitumor activity can be provided.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: September 2, 2014
    Assignee: Astellas Pharma Inc.
    Inventors: Yoshinori Naoe, Takeshi Inoue, Yasuhiko Kano
  • Publication number: 20140243499
    Abstract: The invention relates to peptide derivatives (peptides and pseudo-peptides) and use thereof as vectors for molecules of interest. The invention also relates to conjugates containing a peptide derivative of the invention bound to a molecule of interest. The peptides and prodrug conjugates of the invention can be used to vectorise molecules of pharmaceutical or diagnostic interest, such as, for example, therapeutic molecules, imaging or diagnostic agents, or molecular probes, across cell membranes, and notably to promote their transport across the blood-brain barrier (BBB).
    Type: Application
    Filed: May 14, 2014
    Publication date: August 28, 2014
    Applicants: Vect-Horus, Centre National De La Recherche Scientifique, Universite D'Aix Marseille
    Inventors: MICHEL KHRESTCHATISKY, MARION DAVID, YVES MOLINO, PATRICK VLIEGHE
  • Publication number: 20140243500
    Abstract: The present invention relates to calibration and normalization systems and methods for ensuring the quality of radiopharmaceuticals during the synthesis thereof, such as radiopharmaceuticals used in Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT).
    Type: Application
    Filed: September 28, 2012
    Publication date: August 28, 2014
    Inventors: Torgrim Engell, Julian Grigg
  • Patent number: 8815214
    Abstract: Provided is a family of intramolecularly quenched imaging agents for use in both in vivo and in vitro imaging that contain at least one enzymatically cleavable oligopeptide and two fluorophores or a fluorophore and a quencher. When subjected to proteolytic cleavage, at least one fluorophore is unquenched and becomes capable of producing a fluorescent signal upon excitation with light of an appropriate wavelength. Also provided are in vivo and in vitro imaging methods using such imaging agents.
    Type: Grant
    Filed: January 17, 2009
    Date of Patent: August 26, 2014
    Assignee: VisEn Medical, Inc.
    Inventors: Milind Rajopadhye, Kevin Groves, Dorin V. Preda
  • Patent number: 8815804
    Abstract: Disclosed are compositions and methods useful for targeting tumors, sites of injury and blood clots. The compositions and methods are based on peptide sequences that selectively bind to and home to tumors, sites of injury and blood clots in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to tumors, sites of injury and blood clots.
    Type: Grant
    Filed: February 5, 2007
    Date of Patent: August 26, 2014
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Jan Pilch
  • Patent number: 8815539
    Abstract: Melanin or inorganic fertilizers are produced from fermentation leachates or from low-cost nutrient-rich solutions. The method for producing the melanin or inorganic fertilizer comprises repetitive trophic cycling in the controlled conditions of primary and secondary bioreactors. Nutrients are cycled between microorganisms such as bacteria, yeast and fungi and black soldier fly larvae, Hermetia illucens. Polysaccharides are partly converted into natural melanins or inorganic fertilizer, which are difficult to biodegrade and hence accumulate in the bioreactors. The method can employ, as a source of nutrients, leachates produced from food waste or from sugar-rich liquid waste of the food industry. These leachates can be used raw or can be augmented with low-cost sugar-rich solutions such as molasses, hydrolyzed cellulose or starch. The method is inexpensive and does not require the use of expensive chemically-defined culture media.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: August 26, 2014
    Assignee: River Road Research, Inc.
    Inventors: Radu Popa, Kenneth H. Nealson
  • Publication number: 20140228302
    Abstract: Compositions and methods of treating or preventing disease or injury to a human patient or biological material undergoing ischemic or hypoxic conditions.
    Type: Application
    Filed: February 5, 2014
    Publication date: August 14, 2014
    Applicant: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Fuqiang Ruan, Edward A. Winter, Thomas L. Deckwerth
  • Publication number: 20140220159
    Abstract: The present invention relates to peptidomimetics for reactivating p53. Methods of using the peptidomimetics are also disclosed.
    Type: Application
    Filed: January 21, 2014
    Publication date: August 7, 2014
    Inventors: Paramjit S. ARORA, Quintin PAN, Anna MAPP
  • Patent number: 8796418
    Abstract: Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: August 5, 2014
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Loren D. Walensky, Gregory L. Verdine, Susan Korsmeyer
  • Patent number: 8796221
    Abstract: Disclosed herein are methods of making cyclosporin A Form 2.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: August 5, 2014
    Assignee: Allergan, Inc.
    Inventors: Ke Wu, Scott W. Smith
  • Publication number: 20140213757
    Abstract: The present invention is directed to a modified synthesis cassette (110) that enables flexible, in-process monitoring of radiopharmaceutical synthesis. Also provided is a method for radiopharmaceutical synthesis using the modified synthesis cassette (110).
    Type: Application
    Filed: September 18, 2012
    Publication date: July 31, 2014
    Inventors: Jonathan R Shales, Roger P Pettitt
  • Patent number: 8791062
    Abstract: The present disclosure provides peptides and peptide compositions, which facilitate the delivery of an active agent or an active agent carrier wherein the compositions are capable of penetrating the stratum corneum (SC) and/or the cellular membranes of viable cells.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: July 29, 2014
    Assignee: The Regents of the University of California
    Inventors: Tracy Hsu, Samir M. Mitragotri
  • Publication number: 20140205681
    Abstract: The present invention relates to peptidomimetics for reactivating p53. Methods of using the peptidomimetics are also disclosed.
    Type: Application
    Filed: January 21, 2014
    Publication date: July 24, 2014
    Inventors: Paramjit S. ARORA, Quintin PAN, Anna MAPP
  • Publication number: 20140205668
    Abstract: An aspect of embodiments of the invention relates to surface modified proteinaceous spherical particles (SMOP). SMOPs according to an embodiment of the invention may comprise a protein layer and an amyloid-binding moiety bound to the protein. In an embodiment, the protein layer is spherical in shape and comprises proteins linked to each other by disulfide bonds. It is suggested that SMOPs are effective in preventing formation of amyloid and aggregation of A? when administered to a patient in need thereof.
    Type: Application
    Filed: August 8, 2012
    Publication date: July 24, 2014
    Applicant: BAR-ILAN UNIVERSITY
    Inventors: Shai Rahimipour, Michal Richman
  • Patent number: 8785394
    Abstract: Disclosed herein are methods of treating diseases of the eye by administering to the subconjunctival space a formulation comprising cyclosporin A form 2 and a hydrogel.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: July 22, 2014
    Assignee: Allergan, Inc.
    Inventors: Wendy M. Blanda, Mayssa Attar
  • Patent number: 8785375
    Abstract: The present invention relates to cyclic cationic peptides and their use in the treatment of microbial infections.
    Type: Grant
    Filed: August 22, 2012
    Date of Patent: July 22, 2014
    Assignee: Novabiotics Ltd.
    Inventor: Deborah O'Neil
  • Publication number: 20140194361
    Abstract: The invention relates to compositions of vault complexes containing cell adhesion inhibiting agents, such as a RGD-peptide, and methods of using the vault complexes in the treatment of diseases, such as chronic kidney disease.
    Type: Application
    Filed: October 9, 2013
    Publication date: July 10, 2014
    Inventors: Susanne B. Nicholas, Leonard H. Rome, Valerie A. Kickhoefer
  • Publication number: 20140194358
    Abstract: Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration.
    Type: Application
    Filed: October 28, 2013
    Publication date: July 10, 2014
    Applicant: Children's Medical Center Corporation
    Inventors: Avner Adini, Robert D'Amato
  • Publication number: 20140194345
    Abstract: The present invention relates generally to novel depsipeptides, to methods for the preparation of these novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders.
    Type: Application
    Filed: December 3, 2013
    Publication date: July 10, 2014
    Inventors: Aaron J. Peoples, Dallas Hughes, Losee Lucy Ling, William Millett, Anthony Nitti, Amy Spoering, Victoria Alexandra Steadman, Jean-Yves Christophe Chiva, Linos Lazarides, Michael Kenyon Jones, Karine Gaelle Poullenec, Kim Lewis
  • Patent number: 8772445
    Abstract: A compound having the general structure R1, R2, R3 and R4 being selected from the group consisting of a hydrogen atom (H) and a C1-C20 alkyl, and R5 being a phenyl radical.
    Type: Grant
    Filed: November 20, 2008
    Date of Patent: July 8, 2014
    Assignee: Helmholtz-Zentrum Fuer Ozeanforschung Kiel (Geomar)
    Inventors: Johannes Imhoff, Zhiguo Yu, Gerhard Lang, Jutta Wiese, Holger Kalthoff, Stefanie Klose
  • Patent number: 8772245
    Abstract: The present invention relates generally to crystalline forms of cyclosporine A and particularly to a newly identified form of cyclosporine A. The invention further relates to methods for its preparation and to methods for treating certain ocular disorders.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: July 8, 2014
    Assignee: Allergan, Inc.
    Inventors: Anuradha V. Gore, Kiomars Karami, Ke Wu, Richard S. Graham, Scott W. Smith
  • Patent number: RE45003
    Abstract: Characterization of the biosynthetic gene cluster for the lantibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine are described.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: July 8, 2014
    Assignee: Novacta Biosystems Limited
    Inventors: Steven Boakes, Jesus Cortes Bargallo, Michael John Dawson